Q2 2026 Biostem Technologies Inc Earnings Call Transcript
Key Points
- BioStem Technologies Inc (BSEM) successfully completed its uplisting to the Nasdaq Capital Market, enhancing visibility and access to capital markets.
- Hospital revenue increased sequentially to $6.7 million, reflecting strong execution of the hospital-focused strategy and expansion of the direct sales force.
- The company raised its full-year 2026 revenue guidance to $26-$29 million, up from the prior range of $25-$29 million, driven by continued growth in the hospital segment.
- BioStem Technologies Inc (BSEM) received eight new US design patents for its fenestrated human placental allograft designs, strengthening product differentiation and intellectual property protection.
- The company is on track to launch its first 510(k) cleared product later this year, which could provide a competitive edge and support portfolio expansion.
- Management expects significant gross margin improvement (15-20 points) following the in-house manufacturing transfer of NEOX and CLARIX products, which is planned to begin in the first half of 2027.
- BioStem Technologies Inc (BSEM) reported a GAAP net loss of $9 million in Q2 2026, a significant decline from net income of $10,000 in the same period last year.
- Cash and cash equivalents decreased sharply to $7 million as of June 30, 2026, from $13.7 million at the end of Q1, with operating cash use of $5.5 million during the quarter.
- The company faces a $10 million contingent consideration payment related to a milestone, which it is still working to finance, potentially leading to dilution or additional debt.
- Gross margin is expected to face modest pressure in the second half of 2026 due to the use of discounted pre-existing inventory, which could temporarily impact profitability.
- The physician office market remains weak, with management noting that one quarter of stronger results does not indicate a durable recovery, and they expect only gradual stabilization.
- Operating expenses increased to $13.2 million in Q2, driven by continued investment in the commercial organization, which may pressure near-term profitability.
Thank you. Good afternoon and welcome everyone to the BioStem Technologies second-quarter 2026 earnings call. Today's conference is being recorded.
(Operator Instructions)
At this time, I'd like to turn the conference over to Tripp Taylor, Investor Relations. Please go ahead.
Good afternoon, everyone, and thank you for joining our conference call to discuss BioStemâ s second-quarter 2026 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company's Chairman and Chief Executive Officer; Bransedon Poe, the company's Chief Financial Officer; and Barry Hassett, the company's Chief Commercial Officer.
Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These risks and uncertainties are more fully described in our press release issued today and in our filings with the US Securities and Exchange Commission.
Our SEC filings can
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
